运动神经元疾病治疗的全球市场:洞察，竞争情形，市场预测:2032年

预计在2025年至2032年的预测期内，运动神经元疾病 (MND) 治疗市场将以5.87%的复合年增长率成长。由于肌萎缩侧索硬化症 (ALS) 和脊髓性肌肉萎缩症 (SMA) 等运动神经元疾病的盛行率不断上升，对运动神经元疾病 (MND) 治疗的需求正在显着增长。人们越来越意识到早期和准确诊断的重要性，这进一步推动了市场发展势头。此外，生物疗法的显着转变，提供了更有针对性和更有效的治疗选择，正在改变治疗格局。再加上研发投入的不断增加以及 MND 治疗领域的持续技术创新，为市场扩张创造了极为有利的环境。综合来看，这些因素将使运动神经元疾病 (MND) 治疗市场在 2025 年至 2032 年的预测期内保持强劲持续的成长。

运动神经元疾病治疗市场动态：

根据 Taylor & Francis Online 发布的最新数据（2025 年），全球肌萎缩侧索硬化症 (ALS) 的负担预计将稳定增加。预计2022年报告的ALS病例约为32,893例，到2030年将成长10%以上，达到36,308例。这一上升趋势不仅反映了盛行率的上升，也凸显了诊断能力的提高和疾病意识的增强。

DelveInsight的2023年市场分析显示，在美国、英国、德国、法国、义大利、西班牙和日本等七个主要市场，ALS的盛行率约为67,000例，这佐证了这一点。这表明，在现有的医疗保健体系中，对有效的治疗干预措施的需求巨大。根据澳洲运动神经元疾病协会 (MND Australia) 2024 年的数据，每天至少有两人被诊断出患有运动神经元疾病 (MND)，目前约有 2,688 人患有该疾病，这凸显了对可及治疗策略的迫切需求。

就脊髓性肌肉萎缩症 (SMA) 而言，这是一种罕见但严重的遗传性神经肌肉疾病。脊髓性肌肉萎缩症基金会 (SMA) 2023 年估计，目前美国有 10,000 至 25,000 人受其影响。此病的出生盛行率为 1/6,000 至 1/10,000，凸显了早期筛检和介入的重要性。基因疗法，特别是使用腺相关病毒载体进行的SMN1基因替换，已成为突破性的解决方案，显着改善了患者的长期疗效，并在某些情况下恢復了运动功能。

总而言之，运动神经元疾病（尤其是ALS和SMA）的盛行率上升，是全球运动神经元疾病（MND）治疗市场快速扩张的主要驱动力。这些以肌肉无力、呼吸功能障碍以及最终的运动技能丧失为特征的进行性神经系统疾病，日益被视为严重的公共卫生问题。因此，对创新疾病改良疗法的需求日益增长。

在治疗方面，MND治疗的典范转移正在进行中。对于ALS，治疗重点已从缓解症状扩展到开发旨在减缓神经元退化进展的神经保护剂。对于SMA，基因疗法正在重新定义治疗标准，为治癒疾病提供了可能性，并改变了许多患者的疾病轨迹。

同时，监管环境对技术创新的支持力道也不断增加。美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 近期的批准增强了市场信心。尤其是 Zolgensma® (onasemnogene abeparvovec) 的获批，验证了基因疗法的有效性，并加速了针对运动神经元保存和肌肉增强的下一代疗法的投资。

市场开发公司也在加强研发力度，以将先进的标靶疗法商业化。例如，2023 年 4 月，Biogen Inc. 获得 FDA 加速批准，其鞘内注射 QALSODY™（通用名：tofersen）用于治疗已确诊超氧化物歧化酶 1 (SOD1) 基因突变的成人肌萎缩侧索硬化症 (ALS)。这项决定是基于血浆神经丝轻链 (NfL) 水平的降低，神经丝轻链 (NfL) 是一种与神经元损伤相关的生物标誌物，这标誌着生物标记驱动的治疗发展迈出了重要一步。

总而言之，ALS 和 SMA 的盛行率和认知度不断提高，加上治疗创新的进步和有利的监管环境，正在创造一个强劲而充满活力的运动神经元疾病治疗市场。这些发展为该领域在 2025 年至 2032 年的预测期内实现持续成长和持续的科学突破奠定了基础。

然而，高昂的治疗费用以及监管机构和政府的严格指导方针是限制运动神经元疾病治疗市场成长的主要限制因素。

运动神经元疾病治疗市场区隔分析：

按药物类别划分的运动神经元疾病治疗市场中，预计存活运动神经元 (SMN) 激动剂类别将在 2024 年占据最大市场占有率。此类别的成长主要得益于脊髓性肌肉萎缩症 (SMA) 盛行率的上升以及 SMN1 标靶疗法带来的诱人疗效。 SMN 蛋白对于运动神经元的存活和功能至关重要，而运动神经元对于随意肌肉运动至关重要。 SMN 激动剂透过增强 SMN 蛋白的生成发挥作用，帮助维持运动功能、减缓病情进展并改善 SMA 患者的整体生活品质。

例如，根据英国国家医疗服务体系 (NHS England) (2023) 的数据，英国每年约有 70 名 SMA 儿童出生。同样，澳洲人类遗传学会 (2024) 报告称，每 10,000 人中就有 1 人出生时患有 SMA，每 40 人中就有 1 人是相关基因突变的健康携带者，这凸显了 SMA 的高风险人群以及对有效干预措施的迫切需求。

SMN 标靶疗法的一个显着优势是其能够提供跨类型疗效，从而为不同 SMA 亚型（从严重的 1 型到较轻的 3 型）带来临床益处。例如，被诊断为最严重 SMA（1 型）的婴儿在运动功能方面表现出显着改善，达到了无需辅助即可坐起等发育里程碑，这在未经治疗的病例中很少见。

除了改善运动功能外，口服 SMN 激动剂疗法还具有改善可及性和依从性的优势，尤其是在儿科患者中。这使得长期治疗管理更加可行且对患者更友好，有助于提高依从性并改善疗效。透过提高SMN蛋白水平，SMN激动剂有助于减缓SMA的进展，缓解相关的神经肌肉症状，并延长生存期，尤其是在早发重症病例中。

不断增加的研发投入和监管发展进一步推动了这一类别的成长。主要的行业参与者正在积极开发下一代SMN标靶疗法，以提高疗效和便利性。一个显着的例子是罗氏公司于2025年2月宣布，美国食品药物管理局(FDA)已批准Evrysdi® (risdiplam)片剂的新药申请(NDA)。 Evrysdi是一种SMN2前mRNA剪接修饰剂，旨在治疗SMA，该疾病是由5q染色体基因突变导致SMN蛋白缺失引起的。该片剂是一种口服全身性治疗药物，可在家服用，减少了住院输液的需求，使患者和家属更容易获得治疗。

这些因素预计将推动细分市场的发展，并最终推动全球运动神经元疾病治疗市场的发展。

预计到2024年，北美将占据全球运动神经元疾病治疗市场的最大占有率，这得益于其关键的结构性和战略优势。该地区的主导地位主要源于脊髓性肌肉萎缩症 (SMA) 和肌萎缩侧索硬化症 (ALS) 等运动神经元疾病的盛行率不断上升，这持续增加了医疗保健系统对有效治疗方案的需求。此外，该地区拥有强劲的製药环境，大型生物技术和製药公司积极开发、临床试验和商业化创新疗法。新产品审批速度维持较高水平，并得益于良好的监管架构。特别是，美国食品药物管理局 (FDA) 等机构已推出罕见疾病药物加速审批流程，支持快速提供尖端的MND治疗方案。加重的疾病负担、强大的研发活动以及积极的监管支持等因素共同巩固了北美在运动神经元疾病治疗市场的全球领先地位。

根据美国疾病管制与预防中心 (CDC, 2025) 的最新数据，2022 年美国将记录约 33,000 例肌萎缩侧索硬化症 (ALS) 病例，预计到 2030 年这一数字将增加 10% 以上，超过 36,000 例。同样，美国医学会 (2024) 报告称，2024 年美国每 14,694 名新生儿中就有 1 人将被诊断患有脊髓性肌肉萎缩症 (SMA)，这凸显了北美运动神经元疾病 (MND) 负担的日益加重。

针对运动神经元的疗法越来越多地被用来对抗这些渐进性且往往致命的疾病。具体而言，治疗着重于替换缺失或缺陷的SMN1基因，提供功能性拷贝，以维护运动神经元健康并减缓肌肉退化。美国国立卫生研究院（2022年）指出，据估计，加拿大每年每10,000名新生儿中约有6,000至1人患有SMA，这支持了这一趋势，凸显了该地区对及时诊断和高级干预的需求。

SMA盛行率的上升是北美运动神经元疾病治疗市场成长的主要驱动力，从而导致对疾病修饰疗法的需求增加。由于SMA通常发生在婴儿期和幼儿期，因此早期基因筛检和创新疗法（例如针对SMN的基因疗法）的需求日益迫切，从而刺激了研发投资和治疗方法的开发。

推动该地区市场扩张的一个主要因素是严格的监管环境。美国食品药物管理局 (FDA) 正在透过为有前景的药物提供快速通道和突破性疗法认定，加速运动神经元疾病 (MND) 治疗的进展。值得注意的是，用于脊髓性肌肉萎缩症 (SMA) 的基因疗法 Zolgensma® 获得了加速审批，这标誌着疾病修饰治疗取得了突破，并进一步验证了基于基因的治疗方法。

除了监管支援外，美国主要製药公司的持续创新也增强了市场发展动能。例如，2023 年 4 月，百健公司 (Biogen Inc.) 宣布其鞘内注射 QALSODY™（通用名：tofersen）已获得 FDA 加速审批，用于治疗已确诊 SOD1 基因突变的肌萎缩侧索硬化症 (ALS) 患者。此审批是基于血浆中 IL-16（一种与神经元损伤相关的生物标记）的检测结果。QALSODY 作为一种新型标靶疗法在美国市场上销售，该药物能够降低运动神经元疾病患者的神经丝轻链 (NfL) 水平。

不断上升的疾病盛行率、持续的产品创新、监管支持以及行业领导者的策略性举措，都是推动北美运动神经元疾病治疗市场在 2025 年至 2032 年预测期内强劲增长的因素。

运动神经元疾病治疗市场的主要参与者：

运动神经元疾病治疗市场的主要参与者包括 Biogen、三菱化学集团株式会社、罗氏製药有限公司、大冢控股株式会社、赛诺菲、Ionis Pharmaceuticals, Inc.、诺华公司、EDW Pharmace Inc.、PTC Therapeutics, Inc.、中外株式会社和 AMYLYXceticals。

运动神经元疾病治疗市场的最新进展：

• 2025年6月，罗氏公司宣布，欧盟委员会 (EC) 批准延长 Evrysdi® (risdiplam) 的说明书，为脊髓性肌肉萎缩症 (SMA) 患者添加一种新的常温片剂型。这项进展提高了治疗的便利性和可近性，尤其对于需要灵活居家给药的患者而言。
• 2025年1月，百健公司 (Biogen Inc.) 宣布，美国食品药物管理局 (FDA) 已受理 Nusinersen 高剂量製剂的监管申请，欧洲药品管理局 (EMA) 也已批准该申请。这项进展标誌着透过优化剂量以改善脊髓性肌肉萎缩症 (SMA) 患者的临床疗效，朝着潜在增强 Nusinersen 治疗效果迈出了重要一步。
• 2022年9月，Amylyx Pharmaceuticals, Inc. 宣布，美国食品药物管理局 (FDA) 批准 RELYVRIO™（苯丁酸钠和牛磺酸二醇）用于治疗肌萎缩侧索硬化症 (ALS) 成年患者。此批准标誌着一个重要的里程碑，为患者提供了一种旨在减缓病情进展和保留神经功能的全新治疗选择。

运动神经元疾病治疗市场研究报告的主要发现

• 目前运动神经元疾病治疗市场规模分析（2024 年）及八年市场预测（2025-2032 年）
• 过去三年主要产品/技术发展、合併、收购、合作及合资企业
• 主导运动神经元疾病治疗市场的主要公司
• 运动神经元疾病治疗市场中竞争对手面临的各种机会
• 2024 年和 2025 年的顶级细分市场以及这些细分市场在 2032 年的表现
• 目前运动神经元疾病治疗市场中表现最佳的地区和国家
• 未来公司应关注运动神经元疾病治疗市场成长机会的地区和国家

关于运动神经元疾病治疗的常见问题市场

1. 运动神经元疾病治疗

• 运动神经元疾病 (MND) 治疗是指使用药物介入措施来减缓疾病进展和控制症状。核心疗法旨在延长患者存活期并缓解功能衰退。此外，支持治疗针对肌肉僵硬、痉挛和疼痛等继发症状，提高患者舒适度和整体生活质量，从而改善护理效果并提升医疗价值。

  2. 运动神经元疾病治疗市场

  • 预计在 2025 年至 2032 年的预测期内，运动神经元疾病治疗市场将以 5.87% 的复合年增长率成长。

  3.运动神经元疾病治疗市场的驱动因素

  • 运动神经元疾病治疗的需求受到多种关键因素的驱动，包括早产数量增加及其相关併发症，例如低体温、低血糖、呼吸窘迫和代谢性酸中毒，以及感染和其他新生儿疾病风险的增加。此外，先天性畸形盛行率的上升，以及新兴市场主要公司持续的产品开发和上市活动，也进一步推动了市场的成长。这些因素共同为持续的市场扩张创造了有利环境，预计运动神经元疾病治疗市场将在2025年至2032年期间实现强劲稳定的成长。

  4.运动神经元疾病治疗市场的主要公司

  • 运动神经元疾病治疗市场的主要参与者包括百健（Biogen）、三菱化学集团株式会社、罗氏製药有限公司、大冢控股株式会社、赛诺菲、Ionis Pharmaceuticals, Inc.、诺华公司、EDW Pharma, Inc.、PTC Therapeutics, Inc.、中外製药株式会合AMYs。

  5. 运动神经元疾病治疗市场最大占有率的地区

  • 得益于关键的结构性和策略优势，预计到2024年，北美将占据全球运动神经元疾病治疗市场的最大占有率。该地区的主导地位主要源于脊髓性肌肉萎缩症 (SMA) 和肌萎缩侧索硬化症 (ALS) 等运动神经元疾病的盛行率不断上升，这持续增加了医疗保健系统对有效治疗方案的需求。此外，该地区还受益于强劲的医药市场格局，大型生物技术和製药公司正在积极开发、临床测试和商业化创新疗法。新产品审批速度保持较高水平，并得到有利的监管框架的进一步支持。尤其是美国食品药物管理局 (FDA) 等机构已推出罕见疾病药物加速审批途径，支持快速提供尖端的 MND 治疗方案。加重的疾病负担、强劲的研发活动以及积极的监管支持等因素共同巩固了北美作为运动神经元疾病治疗市场全球领导者的地位。

  目录

  第1章 运动神经元疾病治疗市场报告的简介

  第2章 运动神经元疾病治疗市场摘要整理

  第3章 竞争情形

  第4章 法规分析

  • 美国
  • 欧洲
  • 日本
  • 中国

  第5章 运动神经元疾病治疗市场主要原因分析

  • 运动神经元疾病治疗市场的驱动因素
    • 运动神经元疾病盛行率不断上升
    • 对早期准确诊断的需求和认知不断提高
    • 加大运动神经元疾病的投资与创新运动神经元疾病药物研发
  • 运动神经元疾病治疗市场的限制与课题
    • 高昂的治疗费用
    • 监管机构和政府机构的严格指导方针
  • 运动神经元疾病治疗市场的机遇
    • 日益转向个人化与标靶治疗
    • 运动神经元疾病适应症的药物组合不断扩展

  第6章 运动神经元疾病治疗市场上波特的五力分析

  第7章 运动神经元疾病治疗市场评估

  • 各类药物
    • NMDA（N-甲基-D-天门冬胺酸）受体拮抗剂
    • SOD1 突变激动剂
    • α-2 肾上腺素激动剂
    • 存活运动神经元 (SMN) 激动剂
    • 其他
  • 各给药途径
    • 口服
    • 非口服
  • 各适应症
    • 肌肉萎缩性脊髓侧索硬化症(ALS)
    • 脊髓性肌萎缩症(SMA)
  • 各流通管道
    • 医院及药局
    • 线上药局
  • 地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区

  第8章 运动神经元疾病治疗市场企业与产品简介

  • Biogen
  • Mitsubishi Chemical Group Corporation
  • F. Hoffmann-La Roche Ltd.
  • Otsuka Holdings Co., Ltd.
  • Sanofi
  • Ionis Pharmaceuticals, Inc.
  • Novartis AG
  • EW Pharma, Inc.
  • PTC Therapeutics, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • AMYLYX Pharmaceuticals

  第9章 KOL的见解

  第10章 计划方法

  第11章 关于DelveInsight

  第12章 免责声明和咨询方式

Motor Neuron Disease Treatment Market by Drug Class (NMDA (N-methyl-D-aspartate) Receptor Antagonist, SOD1 Gene Mutation Agonist, Alpha-2 Adrenergic Agonist, Survival Motor Neuron (SMN) Agonist, and Others), Route of Administration (Oral and Parenteral), Indication (Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and Others), Distribution Channel (Hospitals and Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of motor neuron diseases and increasing investments and innovations in the research and development of MND drugs.

The motor neuron disease treatment market is estimated to grow at a CAGR of 5.87% during the forecast period from 2025 to 2032. The demand for motor neuron disease (MND) treatment is experiencing significant growth, driven by the rising prevalence of motor neuron disorders such as Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and others. Increasing awareness about the importance of early and accurate diagnosis is further accelerating market momentum. Moreover, a notable shift toward biological therapies which offer targeted and more effective treatment options is transforming the therapeutic landscape. This, combined with increasing investments and continuous innovation in the research and development of MND therapies, is fostering a highly favorable environment for market expansion. These factors collectively position the motor neuron disease treatment market for robust and sustained growth throughout the forecast period from 2025 to 2032.

Motor Neuron Disease Treatment Market Dynamics:

According to recent data published by Taylor & Francis Online (2025), the global burden of Amyotrophic Lateral Sclerosis (ALS) is projected to grow steadily. From approximately 32,893 reported cases in 2022, the number was expected to increase by over 10%, reaching an estimated 36,308 cases by 2030. This upward trend not only reflected a rise in incidence rates but also highlighted improvements in diagnostic capabilities and heightened disease awareness.

Supporting this, a 2023 market analysis by DelveInsight revealed that across the seven major markets including the United States, United Kingdom, Germany, France, Italy, Spain, and Japan, the prevalence of ALS stood at around 67,000 cases. This indicated a substantial demand for effective therapeutic interventions within well-established healthcare systems. Regionally, Australia mirrors this growing burden, data from MND Australia (2024), showed that at least two individuals were diagnosed with motor neuron disease (MND) each day, with approximately 2,688 people who were currently living with that condition, underscoring the pressing need for accessible treatment strategies.

In the case of Spinal Muscular Atrophy (SMA), a rare but severe genetic neuromuscular disorder, the Spinal Muscular Atrophy Foundation (2023) estimated that between 10,000 and 25,000 individuals were currently affected in the United States. The condition had a birth prevalence of approximately 1 in every 6,000 to 10,000 live births, emphasizing the critical importance of early screening and intervention. Gene therapy, particularly SMN1 gene replacement using adeno-associated viral vectors, has emerged as a transformative solution, significantly improving long-term outcomes and, in some instances, restoring motor function.

Collectively, the rising prevalence of motor neuron diseases particularly ALS and SMA is a key driver behind the rapid expansion of the global MND treatment market. These progressive neurological disorders, characterized by muscle weakness, respiratory compromise, and eventual loss of mobility, are increasingly recognized as serious public health concerns. As a result, there is mounting demand for innovative, disease-modifying therapies.

Therapeutically, the MND treatment landscape is undergoing a paradigm shift. In ALS, the focus is expanding beyond symptomatic relief to the development of neuroprotective agents designed to slow the progression of neuronal degeneration. In SMA, gene therapy has redefined the standard of care, offering potentially curative benefits and altering the disease trajectory for many patients.

At the same time, the regulatory environment is becoming more supportive of innovation. Recent approvals by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have bolstered confidence in the market. Notably, the approval of Zolgensma(R) (onasemnogene abeparvovec) has validated gene therapy approaches and accelerated investment in next-generation treatments that target motor neuron preservation and muscle function enhancement.

Market players are also intensifying their research and development efforts to commercialize advanced targeted therapies. For example, in April 2023, Biogen Inc. received FDA accelerated approval for QALSODY(TM) (tofersen), an intrathecal injection indicated for the treatment of ALS in adults with a confirmed mutation in the superoxide dismutase 1 (SOD1) gene. The decision was based on reductions in plasma neurofilament light chain (NfL) levels, a biomarker linked to neuronal damage, marking a significant step forward in biomarker-driven therapeutic development.

In conclusion, the growing incidence and improved recognition of ALS and SMA, coupled with advancements in therapeutic innovation and a favorable regulatory backdrop, are collectively shaping a robust and dynamic motor neuron disease treatment market. These developments position the sector for sustained growth and ongoing scientific breakthroughs throughout the forecast period from 2025 to 2032.

However, the high cost of the treatment and stringent guidelines by regulatory bodies and governments, among others are some of the key constraints that may limit the growth of the motor neuron disease treatment market.

Motor Neuron Disease Treatment Market Segment Analysis:

Motor Neuron Disease Treatment Market by Drug Class (NMDA (N-methyl-D-aspartate) Receptor Antagonist, SOD1 Gene Mutation Agonist, Alpha-2 Adrenergic Agonist, Survival Motor Neuron (SMN) Agonist, and Others), Route of Administration (Oral and Parenteral), Indication (Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and Others), Distribution Channel (Hospital and Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the drug class segment of the motor neuron disease treatment market, the survival motor neuron (SMN) agonist category is estimated to account for the largest market share in 2024. The growth of this category is primarily driven by the increasing prevalence of Spinal Muscular Atrophy (SMA) and the compelling therapeutic benefits associated with SMN1-targeted treatments. The SMN protein is critical for the survival and function of motor neurons, which are essential for voluntary muscle movement. SMN agonists work by enhancing the production of SMN protein, helping to preserve motor function, delay disease progression, and improve the overall quality of life for patients living with SMA.

For instance, according to NHS England (2023), approximately 70 children were born with SMA each year in the United Kingdom. Similarly, the Human Genetics Society of Australia (2024) reported that 1 in 10,000 individuals were born with SMA, while 1 in 40 people were healthy carriers of the associated genetic mutation highlighting the significant at-risk population and the urgent need for effective interventions.

One notable advantage of SMN-targeted therapies is their ability to provide cross-type efficacy, offering clinical benefits across different forms of SMA, from severe Type 1 to milder Type 3. For example, infants diagnosed with Type 1 SMA typically the most severe form have demonstrated remarkable improvements in motor function, including reaching developmental milestones such as sitting unassisted, an outcome that is rare in untreated cases.

In addition to motor function improvements, SMN agonist therapies offer the benefit of oral formulations, enhancing treatment accessibility and compliance, especially among pediatric patients. This makes long-term treatment management more feasible and patient-friendly, contributing to better adherence and improved outcomes. By boosting SMN protein levels, SMN agonists help slow the progression of SMA, mitigate its associated neuromuscular symptoms, and prolong survival, particularly in early-onset and severe cases.

Further fueling this category's growth is the increase in R&D investments and regulatory advancements. Key industry players are actively developing next-generation SMN-targeted treatments to improve efficacy and convenience. A notable example is from February 2025, when Roche announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for a tablet formulation of Evrysdi(R) (risdiplam). Evrysdi is an SMN2 pre-mRNA splicing modifier, designed to treat SMA caused by mutations in the chromosome 5q gene, which result in a deficiency of the SMN protein. This tablet formulation offers an oral, systemic treatment alternative that can be taken at home, reducing the need for hospital-based infusions and making care more accessible for patients and families.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of motor neuron disease treatment across the globe.

North America is expected to dominate the overall motor neuron disease treatment market:

North America is expected to hold the largest share of the global motor neuron disease treatment market in 2024, driven by a combination of key structural and strategic advantages. This regional dominance is primarily attributed to the rising prevalence of motor neuron disorders such as Spinal Muscular Atrophy (SMA) and Amyotrophic Lateral Sclerosis (ALS), which continue to place increasing demand on healthcare systems for effective treatment solutions. Additionally, the region benefits from a robust pharmaceutical landscape, with leading biotech and pharmaceutical companies actively engaged in the development, clinical trials, and commercialization of innovative therapies. The pace of new product approvals remains high, further supported by favorable regulatory frameworks. Notably, agencies such as the U.S. Food and Drug Administration (FDA) have implemented accelerated approval pathways for rare disease drugs, helping to fast-track the availability of cutting-edge treatments for MNDs. Collectively, these factors such as the rising disease burden, strong R&D activity, and proactive regulatory support are solidifying North America's position as the global leader in the motor neuron disease treatment market.

According to recent data from the Centers for Disease Control and Prevention (CDC, 2025), approximately 33,000 cases of Amyotrophic Lateral Sclerosis (ALS) were recorded in the U.S. in 2022, with the number projected to rise by over 10% to exceed 36,000 cases by 2030. Similarly, the American Medical Association (2024) reported that 1 in every 14,694 newborns in the U.S. was diagnosed with Spinal Muscular Atrophy (SMA) in 2024, underscoring the growing burden of motor neuron diseases (MNDs) in North America.

To combat these progressive and often fatal disorders, motor neuron-targeted therapies are increasingly being adopted, particularly those focused on replacing defective or missing SMN1 genes, thereby providing functional copies to preserve motor neuron health and slow muscular degeneration. Supporting this trend, the National Institutes of Health (2022), noted that in Canada, between 1 in 6,000 to 10,000 babies were born with SMA annually, highlighting a regional need for timely diagnosis and advanced interventions.

The rising incidence of SMA is a key driver of growth in the North American motor neuron disease treatment market, as it has led to increased demand for disease-modifying therapies. Given that SMA often manifests in infancy or early childhood, there is a heightened urgency for early genetic screening and innovative treatments such as SMN-targeted gene therapy, which has spurred substantial R&D investment and therapeutic development.

A significant enabler of market expansion in the region is the proactive regulatory environment. The U.S. Food and Drug Administration (FDA) has accelerated progress in the MND treatment landscape by offering fast-track and breakthrough therapy designations for promising drugs. Notably, Zolgensma(R), a gene therapy for SMA, received accelerated approval, marking a breakthrough in disease-modifying treatment and further validating gene-based approaches.

In addition to regulatory support, ongoing innovation by leading U.S.-based pharmaceutical companies is reinforcing market momentum. For example, in April 2023, Biogen Inc. announced that the FDA had granted accelerated approval for QALSODY(TM) (tofersen), an intrathecal injection indicated for ALS patients with a confirmed SOD1 gene mutation. The approval was based on the drug's ability to reduce plasma neurofilament light chain (NfL) levels, a biomarker linked to neuronal damage, making QALSODY available in the U.S. market as a new targeted treatment option.

Collectively, the combination of increasing disease prevalence, continuous product innovation, regulatory support, and strategic initiatives by major industry players is expected to drive robust growth in the North American motor neuron disease treatment market throughout the forecast period from 2025 to 2032.

Motor Neuron Disease Treatment Market Key Players:

Some of the key market players operating in the motor neuron disease treatment market include Biogen, Mitsubishi Chemical Group Corporation, F. Hoffmann-La Roche Ltd., Otsuka Holdings Co., Ltd., Sanofi, Ionis Pharmaceuticals, Inc., Novartis AG, EDW Pharma, Inc., PTC Therapeutics, Inc., Chugai Pharmaceutical Co., Ltd., AMYLYX Pharmaceuticals, and others.

Recent Developmental Activities in the Motor Neuron Disease Treatment Market:

• In June 2025, Roche announced that the European Commission (EC) had approved a label extension for Evrysdi(R) (risdiplam), allowing the inclusion of a new room-temperature stable tablet formulation for individuals living with Spinal Muscular Atrophy (SMA). This advancement enhances treatment convenience and accessibility, particularly for patients who require flexible, at-home administration.
• In January 2025, Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) had accepted the company's supplemental New Drug Application (sNDA), and the European Medicines Agency (EMA) had validated its application for a higher dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA). This development marks an important step toward potentially enhancing the therapeutic benefits of nusinersen by optimizing dosing for improved clinical outcomes in SMA patient.
• In September 2022, Amylyx Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved RELYVRIO(TM) (sodium phenylbutyrate and taurursodiol) for the treatment of adults with Amyotrophic Lateral Sclerosis (ALS). This approval marked a significant milestone, offering patients a new therapeutic option aimed at slowing disease progression and preserving neurological function.

Key takeaways from the motor neuron disease treatment market report study

• Market size analysis for current motor neuron disease treatment market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the motor neuron disease treatment market.
• Various opportunities available for the other competitors in the motor neuron disease treatment market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current motor neuron disease treatment market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for motor neuron disease treatment market growth in the coming future?

Target audience who can benefit from this motor neuron disease treatment market report study

• Motor neuron disease treatment product providers
• Research organizations and consulting companies
• Motor neuron disease treatment-related organizations, associations, forums, and other alliances.
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in motor neuron disease treatment
• Various end-users who want to know more about the motor neuron disease treatment market and the latest technological developments in the motor neuron disease treatment market.

Frequently Asked Questions for the Motor Neuron Disease Treatment Market:

1. What are motor neuron disease treatments?

• Motor Neuron Disease (MND) Treatment refers to the use of pharmaceutical interventions aimed at slowing disease progression and managing symptoms. Core treatments are designed to potentially extend patient survival and mitigate functional decline. Additionally, supportive medications target secondary symptoms, such as muscle stiffness, cramps, and pain, to enhance patient comfort and overall quality of life, contributing to improved care outcomes and healthcare value delivery.

2. What is the market for motor neuron disease treatment?

• The motor neuron disease treatment market is estimated to grow at a CAGR of 5.87% during the forecast period from 2025 to 2032.

3. What are the drivers for the motor neuron disease treatment market?

• The demand for motor neuron disease treatment is being driven by several critical factors, including the rising incidence of neonatal disorders such as hypothermia and related complications like hypoglycemia, respiratory distress, metabolic acidosis, and increased risk of infections, along with the growing number of preterm births. Additionally, the increasing prevalence of congenital anomalies and ongoing product development and launch activities by leading market players are further fueling growth. Collectively, these factors are creating a supportive environment for sustained market expansion, positioning the motor neuron disease treatment market for robust and steady growth from 2025 to 2032.

4. Who are the key players operating in the motor neuron disease treatment market?

• Some of the key market players operating in the motor neuron disease treatment market include Biogen, Mitsubishi Chemical Group Corporation, F. Hoffmann-La Roche Ltd., Otsuka Holdings Co., Ltd., Sanofi, Ionis Pharmaceuticals, Inc., Novartis AG, EDW Pharma, Inc., PTC Therapeutics, Inc., Chugai Pharmaceutical Co., Ltd., AMYLYX Pharmaceuticals, and others.

5. Which region has the highest share in the motor neuron disease treatment market?

• North America is expected to hold the largest share of the global motor neuron disease treatment market in 2024, driven by a combination of key structural and strategic advantages. This regional dominance is primarily attributed to the rising prevalence of motor neuron disorders such as Spinal Muscular Atrophy (SMA) and Amyotrophic Lateral Sclerosis (ALS), which continue to place increasing demand on healthcare systems for effective treatment solutions. Additionally, the region benefits from a robust pharmaceutical landscape, with leading biotech and pharmaceutical companies actively engaged in the development, clinical trials, and commercialization of innovative therapies. The pace of new product approvals remains high, further supported by favorable regulatory frameworks. Notably, agencies such as the U.S. Food and Drug Administration (FDA) have implemented accelerated approval pathways for rare disease drugs, helping to fast-track the availability of cutting-edge treatments for MNDs. Collectively, these factors such as the rising disease burden, strong R&D activity, and proactive regulatory support are solidifying North America's position as the global leader in the motor neuron disease treatment market.

Table of Contents

1. Motor Neuron Disease Treatment Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Motor Neuron Disease Treatment Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Motor Neuron Disease Treatment Market Key Factors Analysis

• 5.1. Motor Neuron Disease Treatment Market Drivers
  • 5.1.1. The growing prevalence of motor neuron diseases
  • 5.1.2. Increasing demand and awareness about early and accurate diagnosis
  • 5.1.3. Increasing investments and innovations in the research and development of MND drugs
• 5.2. Motor Neuron Disease Treatment Market Restraints and Challenges
  • 5.2.1. High cost of the treatment
  • 5.2.2. Stringent guidelines by regulatory bodies and government agencies
• 5.3. Motor Neuron Disease Treatment Market Opportunity
  • 5.3.1. Growing shift towards personalized and targeted therapies
  • 5.3.2. Presence of an extensive drug portfolio in the pipeline for motor neuron indications

6. Motor Neuron Disease Treatment Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Motor Neuron Disease Treatment Market Assessment

• 7.1. By Drug Class
  • 7.1.1. NMDA (N-methyl-D-aspartate) Receptor Antagonist
  • 7.1.2. SOD1 Gene Mutation Agonist
  • 7.1.3. Alpha-2 Adrenergic Agonist
  • 7.1.4. Survival Motor Neuron (SMN) Agonist
  • 7.1.5. Others
• 7.2. By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Parenteral
• 7.3. By Indication
  • 7.3.1. Amyotrophic Lateral Sclerosis (ALS)
  • 7.3.2. Spinal Muscular Atrophy (SMA)
  • 7.3.3. Others
• 7.4. By Distribution Channel
  • 7.4.1. Hospital & Retail Pharmacies
  • 7.4.2. Online Pharmacies
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
    • 7.5.1.2. Canada Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
    • 7.5.1.3. Mexico Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
  • 7.5.2. Europe
    • 7.5.2.1. France Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
    • 7.5.2.2. Germany Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
    • 7.5.2.3. United Kingdom Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
    • 7.5.2.4. Italy Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
    • 7.5.2.5. Spain Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
    • 7.5.2.6. Rest of Europe Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
    • 7.5.3.2. Japan Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
    • 7.5.3.3. India Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
    • 7.5.3.4. Australia Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
    • 7.5.3.5. South Korea Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
    • 7.5.3.6. Rest of Asia-Pacific Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
    • 7.5.4.2. Africa Motor Neuron Disease Treatment Market Size in USD million (2022-2032)
    • 7.5.4.3. South America Motor Neuron Disease Treatment Market Size In USD Million (2022-2032)

8. Motor Neuron Disease Treatment Market Company and Product Profiles

• 8.1. Biogen
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Mitsubishi Chemical Group Corporation
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. F. Hoffmann-La Roche Ltd.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Otsuka Holdings Co., Ltd.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Sanofi
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Ionis Pharmaceuticals, Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Novartis AG
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. EW Pharma, Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. PTC Therapeutics, Inc.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Chugai Pharmaceutical Co., Ltd.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. AMYLYX Pharmaceuticals
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

• Table 1: Competitive Analysis
• Table 2: Motor Neuron Disease Treatment Market in Global (2022-2032)
• Table 3: Motor Neuron Disease Treatment Market in Global by Drug Class (2022-2032)
• Table 4: Motor Neuron Disease Treatment Market in Global by Route of Administration (2022-2032)
• Table 5: Motor Neuron Disease Treatment Market in Global by Indication (2022-2032)
• Table 6: Motor Neuron Disease Treatment Market in Global by Distribution Channel (2022-2032)
• Table 7: Motor Neuron Disease Treatment Market in Global by Geography (2022-2032)
• Table 8: Motor Neuron Disease Treatment Market in North America (2022-2032)
• Table 9: Motor Neuron Disease Treatment Market in the United States (2022-2032)
• Table 10: Motor Neuron Disease Treatment Market in Canada (2022-2032)
• Table 11: Motor Neuron Disease Treatment Market in Mexico (2022-2032)
• Table 12: Motor Neuron Disease Treatment Market in Europe (2022-2032)
• Table 13: Motor Neuron Disease Treatment Market in France (2022-2032)
• Table 14: Motor Neuron Disease Treatment Market in Germany (2022-2032)
• Table 15: Motor Neuron Disease Treatment Market in United Kingdom (2022-2032)
• Table 16: Motor Neuron Disease Treatment Market in Italy (2022-2032)
• Table 17: Motor Neuron Disease Treatment Market in Spain (2022-2032)
• Table 18: Motor Neuron Disease Treatment Market in the Rest of Europe (2022-2032)
• Table 19: Motor Neuron Disease Treatment Market in Asia-Pacific (2022-2032)
• Table 20: Motor Neuron Disease Treatment Market in China (2022-2032)
• Table 21: Motor Neuron Disease Treatment Market in Japan (2022-2032)
• Table 22: Motor Neuron Disease Treatment Market in India (2022-2032)
• Table 23: Motor Neuron Disease Treatment Market in Australia (2022-2032)
• Table 24: Motor Neuron Disease Treatment Market in South Korea (2022-2032)
• Table 25: Motor Neuron Disease Treatment Market in Rest of Asia-Pacific (2022-2032)
• Table 26: Motor Neuron Disease Treatment Market in the Rest of the World (2022-2032)
• Table 27: Motor Neuron Disease Treatment Market in the Middle East (2022-2032)
• Table 28: Motor Neuron Disease Treatment Market in Africa (2022-2032)
• Table 29: Motor Neuron Disease Treatment Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Motor Neuron Disease Treatment Market in Global (2022-2032)
• Figure 3: Motor Neuron Disease Treatment Market in Global by Drug Class (2022-2032)
• Figure 4: Motor Neuron Disease Treatment Market in Global by Route of Administration (2022-2032)
• Figure 5: Motor Neuron Disease Treatment Market in Global by Indication (2022-2032)
• Figure 6: Motor Neuron Disease Treatment Market in Global by Distribution Channel (2022-2032)
• Figure 7: Motor Neuron Disease Treatment Market in Global by Geography (2022-2032)
• Figure 8: Motor Neuron Disease Treatment Market in North America (2022-2032)
• Figure 9: Motor Neuron Disease Treatment Market in the United States (2022-2032)
• Figure 10: Motor Neuron Disease Treatment Market in Canada (2022-2032)
• Figure 11: Motor Neuron Disease Treatment Market in Mexico (2022-2032)
• Figure 12: Motor Neuron Disease Treatment Market in Europe (2022-2032)
• Figure 13: Motor Neuron Disease Treatment Market in France (2022-2032)
• Figure 14: Motor Neuron Disease Treatment Market in Germany (2022-2032)
• Figure 15: Motor Neuron Disease Treatment Market in United Kingdom (2022-2032)
• Figure 16: Motor Neuron Disease Treatment Market in Italy (2022-2032)
• Figure 17: Motor Neuron Disease Treatment Market in Spain (2022-2032)
• Figure 18: Motor Neuron Disease Treatment Market in the Rest of Europe (2022-2032)
• Figure 19: Motor Neuron Disease Treatment Market in Asia-Pacific (2022-2032)
• Figure 20: Motor Neuron Disease Treatment Market in China (2022-2032)
• Figure 21: Motor Neuron Disease Treatment Market in Japan (2022-2032)
• Figure 22: Motor Neuron Disease Treatment Market in India (2022-2032)
• Figure 23: Motor Neuron Disease Treatment Market in Australia (2022-2032)
• Figure 24: Motor Neuron Disease Treatment Market in South Korea (2022-2032)
• Figure 25: Motor Neuron Disease Treatment Market in Rest of Asia-Pacific (2022-2032)
• Figure 26: Motor Neuron Disease Treatment Market in the Rest of the World (2022-2032)
• Figure 27: Motor Neuron Disease Treatment Market in the Middle East (2022-2032)
• Figure 28: Motor Neuron Disease Treatment Market in Africa (2022-2032)
• Figure 29: Motor Neuron Disease Treatment Market in South America (2022-2032)
• Figure 30: Market Drivers
• Figure 31: Market Barriers
• Figure 32: Marker Opportunities
• Figure 33: PORTER'S Five Force Analysis